Systemic Spread Is an Early Step in Breast Cancer

Yves Hüsemann,1,10 Jochen B. Geigl,1,9,10 Falk Schubert,2,7,10 Piero Musiani,3 Manfred Meyer,1 Elke Burghart,1 Guido Forni,4 Roland Eils,2,5 Tanja Fehm,6 Gert Riethmüller,8 and Christoph A. Klein1,*

1Department of Pathology, Division of Oncogenomics, University of Regensburg, Regensburg 93053, Germany
2Deutsches Krebsforschungszentrum, Heidelberg 69120, Germany
3Aging Research Centre, Gabriele d’Annunzio University Foundation, Chieti 66013, Italy
4Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Torino, Torino 10126, Italy
5Department of Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology, Universität Heidelberg, Heidelberg 69120, Germany
6Department of Obstetrics and Gynecology, University of Tübingen, Tübingen 72076, Germany
7Cancer Research UK Fission Yeast Functional Genomics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1HH, UK
8Institut für Immunologie, Ludwig-Maximilians Universität München, München 80336, Germany
9Present address: Institute of Human Genetics, Medical University of Graz, Graz 8010, Austria.
10These authors contributed equally to this work.

*Correspondence: christoph.klein@klinik.uni-regensburg.de
DOI 10.1016/j.ccr.2007.12.003

SUMMARY

It is widely accepted that metastasis is a late event in cancer progression. Here, however, we show that tumor cells can disseminate systemically from earliest epithelial alterations in HER-2 and PyMT transgenic mice and from ductal carcinoma in situ in women. Wild-type mice transplanted with single premalignant HER-2 transgenic glands displayed disseminated tumor cells and micrometastasis in bone marrow and lungs. The number of disseminated cancer cells and their karyotypic abnormalities were similar for small and large tumors in patients and mouse models. When activated by bone marrow transplantation into wild-type recipients, 80 early-disseminated cancer cells sufficed to induce lethal carcinoma. Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis.

INTRODUCTION

The final step in cancer progression is metastasis, according to the prevailing view based on several clinical and experimental observations. First, most cancer patients die from metastases and not from their primary disease. Second, early surgery is often the only cure. Third, somatic genetic changes accumulate during local progression (Fearon and Vogelstein, 1990), which was extrapolated to systemic progression since only rare variant cells within the tumor gave rise to metastases (Fidler and Kripke, 1977). Fourth, repeated rounds of in vivo selection led to cell lines with increased metastasis formation (Kang et al., 2003; Minn et al., 2005). However, several clinical and experimental observations are inconsistent with this model. For example, metastasis can develop from small cancers or even in the absence of detectable primary tumors (so-called “cancer of unknown primary,” which ranks among the 10 most frequent cancer diagnoses) (van de Wouw et al., 2002). Furthermore, epidemiological analysis of more than 12,000 breast cancer patients indicated that metastasis might be initiated already 5–7 years before diagnosis of the primary tumor (Engel et al., 2003), suggesting that cancer cells capable to metastasize do not necessarily develop within large tumors. Also, the notion of early metastasis is indirectly supported by gene expression studies (van’t Veer et al., 2002), revealing that patients with poor prognosis can be identified before manifestation of metastasis. Thus, while metastatic spread seems to be somehow genetically predetermined, the time point of metastatic dissemination is not resolved.

SIGNIFICANCE

Patients with large breast cancers are at higher risk to die from metastasis than patients with small tumors. This was thought to reflect the late onset of metastatic spread. The finding, reported here, that the earliest transformed cells are capable of dissemination challenges this notion of late-disseminating, fully transformed cells as sole players in metastasis. It emphasizes that additional genetic or epigenetic events and release from dormancy are critical for productive metastatic growth of early-disseminated cancer cells. Larger tumors may, therefore, affect outgrowth of ectopic cancer cells in ways not yet fully understood. The peculiar nature of disseminated tumor cells—being genetically different from the primary tumor—must be considered when designing targeted adjuvant therapies, which are increasingly applied to eliminate remnant occult metastases.
There is no doubt that a deeper understanding of metastasis is critical for designing more effective therapies for systemic cancer. For example, if metastatic spread occurs late in progression, inhibitors of invasion should be able to prevent it. This, however, was not observed in several clinical trials testing inhibitors of matrix-metalloproteinases (Coussens et al., 2002). If, however, tumor cell dissemination occurs early, the question needs to be addressed how tumor cells can survive in a quiescent state for years at ectopic sites and how tumor dormancy and metastatic outgrowth are regulated. Last but not least, if disseminated tumor cells (DTCs) develop parallel to the primary tumor over a prolonged time, molecular targets on those DTCs need to be urgently identified.

We previously addressed the issue of early versus late metastatic spread by analyzing DTCs in bone marrow of breast cancer patients years before metastatic manifestation (Klein, 2003). Such cells displayed different and fewer aberrations than their matched primary tumors, a finding suggestive of early dissemination (Schmidt-Kittler et al., 2003). Among those DTCs, we identified cancer cells that spread before onset of chromosomal instability (Schardt et al., 2005). Though chromosomal instability has been observed before histological cancer invasion (Chin et al., 2004), breast cancer cells may still disseminate before they become chromosomally instable and prior to microscopic invasion. Interestingly, a subpopulation of these karyotypically normal cancer cells in bone marrow displayed HER-2 amplification (Schardt et al., 2005), a marker of particularly aggressive disease (Al-Kuraya et al., 2004; Kronqvist et al., 2004). Therefore, we thought to search for DTCs in a transgenic HER-2 model of breast cancer at the earliest time point of atypical epithelial transformation. For direct comparison, we report on findings of DTCs in 600 breast cancer patients, including patients with in situ carcinomas.

RESULTS

Epithelial Cells Disseminate in the Premalignant Phase of Murine Breast Cancers

To study tumor progression more closely, we chose BALB/c mice transgenic for the activated rat HER-2/neu gene (BALB-NeuT mice) (Di Carlo et al., 1999), a model that mimics progression of breast cancer in human breast cancer patients years before metastatic manifestation (Klein, 2003). Females of this strain, which are hemizygous for the constitutively activated rat HER-2 gene under control of the MMTV promoter (Muller et al., 1988), develop invasive mammary cancers, while their HER-2 negative siblings (wild-type BALB/c mice) remain tumor free (Boggio et al., 1998). In BALB-NeuT females, mammary epithelia start to express the oncogene at the onset of puberty (weeks 3 to 4 of age) when the mice become responsive to steroid sex hormones. Epithelial hyperplasia can be detected microscopically in the mammary glands at weeks 7–9 (Di Carlo et al., 1999). Progress to in situ carcinomas occurs between weeks 14 and 18. Around week 18 tumors of the mammary glands become palpable or visible, and at weeks 23–30, invasive cancers become apparent (Figure 1A). Mice have to be euthanized between weeks 27 and 33 when primary tumors exceed the size of 1.5 cm in diameter and lung metastases are macroscopically detectable.

The principal goal of the study was to find out when cells expressing the HER-2 transgene disseminate and how they emigrate from the dysplastic breast epithelia. Since the HER-2 receptor is expressed neither in normal lung tissue nor in bone marrow, we concentrated on these organs as preferred sites of metastasis in breast cancer patients. In addition, for the detection of early human cancer spread in bone marrow, staining with anti-cytokeratin (CK) antibodies is specific and sensitive as demonstrated by numerous studies (Braun et al., 2005; Klein, 2003), including simultaneous staining with anti-CK and anti-CD45 panhematopoietic antibodies, which showed CD45-negativity of the cells (Schlimok et al., 1987). Surprisingly, in BALB-NeuT mice, cytokeratin positive (CK+) cells and HER-2 expressing cells (HER-2+) became detectable in bone marrow at as early as 4–9 weeks of age when the most meticulous analysis of the mammary gland could detect areas of atypical ductal hyperplasia (ADH) solely (Figure 1C and Figures S1A–S1C available with this article online). In lung tissue, single HER-2+ tumor cells became detectable from week 9 on, and micrometastases were first visible around week 20 (Table S1 and Figure 1B). Furthermore, the descent of lung micrometastases from mammary tissue was confirmed by the demonstration of mammary-specific alpha casein and lactalbumin transcripts (Figure 1B). The specificity of tumor cell detection by antibodies directed against HER-2 and cytokeratin was further controlled using samples of nontransgenic siblings (Figure 1C).

Despite exponential growth at the primary sites (which is depicted as sum of the total tumor area of the ten mammary glands of BALB-NeuT mice in Figure 1C), the number of CK+ and HER2+ cells in bone marrow rose marginally over the course of time (4/500,000 to 17/500,000 and 1/500,000 to 7/500,000, respectively; Figure 1C). As the total number of cells singly positive for HER-2 and CK were not congruent, we performed double staining for the two antigens. Indeed, not all tumor cells expressed both markers (Figure 1D), suggesting either the existence of heterogeneous tumor cell populations that disseminated to distant sites or different cellular states of the disseminated tumor cells (DTCs). Interestingly, the majority of all detected DTCs (n = 35 cells in 7 mice) were CK+ (71%), while HER-2 was expressed in less than 50%. Similar data were obtained from blood samples (Table S2), although the detection rate of DTCs was lower than in bone marrow.

To test whether early dissemination is only characteristic for BALB-NeuT mice, we also screened bone marrow samples from MMTV-polyomavirus-middle T transgenic mice (Maglione et al., 2001). Though we were unable to establish immunohistochemical detection of tumor cells by antibodies directed against the PyMT antigen, tumor cells were detected at weeks 4–6 in bone marrow by anti-CK staining (Figures S2B and S2D) when only ADH or DCIS was found in mammary tissues (Figure S2A). Lung micrometastases, although difficult to detect by hematoxylin/eosin (HE) staining alone, were found starting from 14 weeks of age (Figure S2B). As in the BALB-NeuT mice, we observed no significant increase in numbers of DTCs in bone marrow during tumor growth (Table S3).

Tumor Cells Emigrate from Transgenic Mammary Gland Transplants in Wild-Type Siblings

Although cytokeratin expression in bone marrow provided strong evidence that the cells were indeed derived from epithelium, we sought direct evidence that the HER-2+ and CK+ cells...
had disseminated from the transformed breast tissue and that the detection of positive cells was not due to extramammary transgene expression. Therefore, we transplanted mammary gland fragments from 3- to 12-week-old transgenic mice (n = 8) orthotopically onto 3-week-old wild-type siblings (n = 16). Each recipient received in one cleared fat pad one tissue fragment of one donor gland. Bone marrow of the recipients was then screened for CK+ and HER-2+ cells 7–26 weeks later. In all recipients of BALB-NeuT mice transplants, we found the HER-2 transgene to be expressed in the grafts at dissection (Figure 2A).

In transplanted wild-type animals, the number of CK+ or HER-2+ cells per 500,000 bone marrow cells (Figures 2B and 2C) was lower than in BALB-NeuT mice (p < 0.0001 and p = 0.002, respectively; Mann-Whitney-test; Figure 2D) but significantly above very rare false-positive cell numbers in control mice (on average 4 in 10^7 bone marrow cells for CK and 6 in 10^7 for HER-2; p < 0.0001 for CK+ and HER-2+ cells, Mann-Whitney-test; Figure 2D). Most likely this reflects the reduced total number of transgenic mammary cells in recipient mice carrying a single transgenic gland compared to BALB-NeuT mice carrying ten transgenic mammary glands. In the transgenic mice, we had analyzed the histology of the largest tumor only, ignoring the remaining 9 mammary glands, while in transplant recipient mice, we scrutinized the single tumor arising from the transgenic mammary graft for signs of invasiveness; the exact staging of the transplant was based on histology after complete serial sectioning. Again, no increase of DTCs in bone marrow was observed from the stage of ADH on up to the stage of invasive cancer (p = 0.26 for CK+ cells and p = 0.83 for HER-2+ cells; Mann-Whitney-test; Figure 2E). The malignant origin of the CK+ or HER-2+ disseminated cells detected in bone marrow was established by single-cell comparative genomic hybridization (CGH) (Klein et al., 1999). Both CK+ and HER-2+ disseminated cells detected in bone marrow was established by single-cell comparative genomic hybridization (CGH) (Klein et al., 1999). Both CK+ and HER-2+ cells isolated from bone marrow displayed multiple chromosomal aberrations in contrast to single leukocytes with normal CGH profiles (Figure 2F and Figure S3). Thus, CGH ascertained the malignancy of the cells, which unambiguously originated from the single transplanted mammary glands.

**Gene Expression Programs Associated with Early Tumor Spread**

In the BALB-NeuT and the PyMT tumor models, dissemination begins shortly after expression of the oncogenic transgene...
without histologically detectable signs of invasion. By light microscopy, the underlying basement membrane showed no gross interruptions. This raised the question of how transformed epithelial cells get out of the atypical hyperplastic areas. However, when examined by electron microscopy, epithelial cells crossing the basement membrane were clearly identified (Figures 3B and 3C for BALB-NeuT mice and Figures S2E and S2F for MMTV-PyMT). In wild-type siblings, neither basement membrane lesions nor emigrating cells were discerned (Figure 3A). The observation that the basement membrane underlying hyperplastic epithelia appeared to be disrupted in BALB-NeuT mice begged the question whether a local activation of proteolytic enzymes could be verified there. We, therefore, applied cDNA array analysis of laser microdissected samples to assess the expression of invasion-associated proteases in ADH at week 9 and large carcinomas at week 27 using a recently established mRNA amplification method (Klein et al., 2002a, 2002b) and hybridized the samples onto a small, dedicated cDNA array (Figure 3D). This array comprised 41 cDNAs encoding matrix-metalloproteases (MMPs) and cathepsins that have earlier been implied in invasion and metastasis (Egeblad and Werb, 2002; Turk et al., 2002). A higher expression of cathepsins Ctsz, Ctsb, Ctsf, Ctsl, Ctsd, and Ctsh; metalloproteases Mmp2, Mmp14, Mmp11, and Timp3; and caspases Casp2 and Casp9 was observed in the early lesions (false discovery rate q = 4.7% for week 9 compared to week 27). The increases in Ctsz (p = 0.0046), Ctsd (p = 0.0046), Mmp2 (p = 0.009), Ctsb (p = 0.0132), and Ctsh (p = 0.0215) expression were significant in a one-sided Wilcoxon test (corrected according to Hochberg). The gene expression patterns at week 9 could be separated from those at week 27 by cluster analysis (cluster robustness index = 0.901; Figure 3D), except for a few outliers. For Mmp2, we found by immunohistochemistry that the protein is not expressed in normal tissue of young mice (week 9, Figure 3E) while strongly expressed in ADH at week 9 in transgenic mice (Figure 3F).

Abundant protease expression in hyperplastic lesions may provide a mechanism for early tumor spread and may be part of a gene regulatory program. We, therefore, determined the expression of the transcription factor Twist, which is a morphogenetic regulator affecting cell migration, a marker of undifferentiated mammary cells, and apparently plays a role in metastasis by regulating both cell invasion and intravasation (Howe et al., 2003; Yang et al., 2004). We compared mRNA expression from several glands from wild-type mice (n = 10), lesions with ADH (n = 16), and areas of invasive cancers dissected from central parts (n = 19) or the invasion front (n = 12) by quantitative PCR. More than 90% of samples from normal mammary glands, central tumor areas, and microdissected areas from the invasion front displayed no or very low levels of Twist mRNA. In contrast, ADH lesions expressed Twist mRNA significantly more often at medium or high levels (p = 0.02, Pearson Chi-square, df = 6, two-sided; Figure 3G), which is in keeping with the notion that the genetic program governing cell dissemination is activated during early transformation.
Evidence that Early-Disseminated Cells Grow into Metastases

The intriguing finding of tumor cells disseminating from preinvasive mammary lesions raised the question of whether they also may grow into metastases. Although the time point of dissemination of metastatic founder cells cannot be determined directly in vivo, we obtained evidence of early systemic spread of founder cells from the following different types of experiments.

We assessed the onset of metastasis relative to primary tumor growth. Histological sections of the lungs were therefore taken to detect the presence of micrometastases and to measure their increase over time (Figure 4B). These could be detected from weeks 20 to 21 onward, a time point at which mostly in situ carcinomas are present at the primary sites (Figure 4A). Since metastases need time to grow, their increase in size paralleling that of the primary lesions supports the conclusion that, at least in some cases, founder cells of metastases had disseminated there earlier and had started to proliferate.

To address this point more directly we performed surgery on BALB-NeuT mice and tried to remove the entire milk line. Only mice older than 18 weeks survived this radical procedure. However, for none of the four 18-week-old mice displaying in situ carcinomas only, we could prevent or reduce the number or size of lung metastases at 27–33 weeks of age (Figure 4B).

To test whether DTCs from large tumors differ from early-disseminated tumor cells, we compared their chromosomal aberrations. We reasoned that, while dissemination occurs early, only genetically further-progressed cancer cells would be able to grow into metastases. We, therefore, analyzed the CGH profiles from tumor cells isolated from bone marrow of mice at week 9 and older than week 27 by hierarchical cluster analysis and support-vector-machine classification (Figure S4). We could not separate the tumor cells from young and old animals and could not detect a significant increase of aberrations from young to old animals (p = 0.3485, exact Wilcoxon rank sum test).

A final set of experiments was directed at tumor progression in wild-type females that had received orthotopic grafts of mammary glands from their 3- to 4-week-old transgenic siblings. In these mice, lung (micro)metastases became detectable at about 40 weeks of age while BALB-NeuT females with autochthonous primary cancers developed lung metastases at 30 weeks on average (Figure 4B). Next, we excised the engrafted glands again at various time points and followed the operated recipients. In recipients (n = 8) from which the grafted glands had been excised...
23–26 weeks after primary transplantation, the mammary tissue was diagnosed with atypical ductal hyperplasia (ADH) in two recipients (Figure 4C), with small invasive cancers of < 9 mm² in four recipients (Figure 4D), and with invasive cancers measuring between 30–35 mm² in the remaining two recipients (tailoring with tumors of BALB-NeuT females before week 18 and at week 22, respectively; Figure 4A). After an additional 11–13 weeks, the operated recipients were sacrificed and screened for local relapse and for tumor cells in bone marrow and lungs (Figure 4G). In none of the animals did we observe a local relapse, but all displayed signs of either minimal residual disease or lung metastasis. Even animals with very small primary lesions in the resected glands carried HER-2+ micrometastasis in their lungs (Figures 4C–4F). We then compared the incidence of lung (micro)metastases between animals that had been diagnosed with invasive cancer and either sacrificed (n = 10) or operated (n = 6) about 26 weeks after mammary tissue transplantation (Figure 4G). Of the 10 animals that were sacrificed at this time point, only one mouse harbored lung micrometastasis. In contrast, of the six animals with resection of the transplanted mammary tissue by surgery at week 26, four of them were diagnosed with metastatic growths (micrometastasis or metastases) in the lungs 11–13 weeks later (p = 0.036; Fisher’s exact test, Figures 4G and 4H). This finding indicates that disseminated cancer cells continued to progress and underscores that the single case with ADH and lung micrometastasis indeed represents progressive minimal residual disease (Figure 4H).

**Early DTCs Can Be Released from Growth Arrest**

Obviously, tumor cell dissemination occurs early but additional mechanisms regulate outgrowth. For example, at no time point could we observe manifest bone metastasis or a frequency of tumor cells of more than 10⁻⁴ in bone marrow of BALB-NeuT mice. Therefore, we asked whether DTCs in bone marrow of young mice could proliferate and generate progeny after stimulation with endogenous growth factors and chemokines as a consequence of irradiation. We transplanted bone marrow from transgenic mice into lethally irradiated nontransgenic siblings. Three transgenic donors (11 weeks old) were euthanized, and 7 to 10 × 10⁶ bone marrow cells were transplanted i.v. into 11 wild-type littermates (Figure 5). The bone marrow of one wild-type BALB/c mouse was transplanted into three siblings as control. Staining with CK antibodies revealed the presence of 4–12 positive cells per 0.5 × 10⁶ bone marrow cells in the inoculum of transgenic mice, indicating a total of 80–240 CK+ cells per recipient mouse. Nineteen to 22 weeks later, all bone marrow transplant recipients became moribund (four animals were found dead before their bone marrow could be analyzed), and autopsy showed massive infiltration of bone marrow by CK+ cells comprising 10%–31% of all nucleated cells (Figures 5A and 5B). Irradiated mice receiving bone marrow from wild-type BALB/c siblings (n = 3) were healthy until they were sacrificed (weeks 19, 28, and 43, respectively) and harbored no CK+ cells in their bone marrow. So far, all isolated single CK+ and HER-2+ cells from recipient animals displayed CGH abnormalities, demonstrating their malignant origin (Figure 2G). Interestingly, no metastases were detected at other sites. The experiments demonstrate that bone-marrow-derived tumor cells disseminated during ADH and can establish bone marrow carcinoma upon transplantation.

**Dissemination of Tumor Cells Is Not Associated with Tumor Size in Human Breast Cancer**

One provocative finding of our study is that, in mouse models of breast cancer, large tumors seed neither more nor genetically
further-advanced cancer cells than do small lesions (Figure 1C and Figure S4, respectively). Thus, the ability of metastatic dissemination does not appear to be the result of selection of tumor cells within the tumor. Rather, the data suggest that tumor cells disseminate early and will be selected for outgrowth at distant sites. We analyzed samples from breast cancer patients to test this hypothesis. From 607 breast cancer patients, we screened bone marrow samples for the presence of DTCs and assessed the number of DTCs for the different sizes of primary tumors. We found no association between the tumor stage and the presence of disseminated cells (p = 0.38, Pearson’s chi-square, df = 6, two-sided; Figure 6A) and specifically, the finding of CK+ cells in patients with ductal carcinoma in situ (DCIS; 13%) and T1-stage patients (22%) was statistically not different (p = 0.093, Pearson’s chi-square test). However, the number of CK+ cells seeded to bone marrow in DCIS patients is significantly higher than observed in control patients (Braun et al., 2000), which were stained using the same antibody (mab A45 B/B3; p = 0.001, Pearson’s chi-square test, 2-sided).

Finally, as in the BALB-NeuT model, we ruled out that tumor cells in bone marrow of patients with large primary tumors are genetically further advanced than disseminated cancer cells of patients with small tumors. We had previously shown that bone marrow samples of breast cancer patients contain CK+ tumor cells without chromosomal aberrations, while the matched primary tumors displayed abnormal karyotypes (Schardt et al., 2005). Such cells apparently disseminated before the onset of chromosomal instability at the primary site, which is thought to occur before stroma invasion (Chin et al., 2004). Furthermore, the malignant origin of cytokeratin-positive cells with normal karyotypes was established by demonstration of loss of heterozygosity (Schardt et al., 2005). We concluded that such cells represent the earliest stages of genetic tumor development. In following up this lead, we examined the chromosomal aberrations of DTCs in bone marrow taken from patients in various tumor stages. Patients were classified into those harboring only cells with CGH abnormalities, only cells without CGH abnormalities, and those harboring both types of tumor cells in bone marrow. We analyzed 105 single cells isolated from 56 patients and could not observe a significant difference between patients with small and large cancers (Figure 6B; p = 0.17, Pearson’s chi-square, df = 4), indicating that the well-known association of large tumor size and development of manifest metastasis is not explained by an increased frequency of genetically progressed cancer cells in bone marrow.

**DISCUSSION**

Here, we provide evidence that dissemination of tumor cells in mouse models of breast cancer as well as in the human disease can occur in preinvasive stages of tumor progression and that the number and genotype of seeded tumor cells is not associated with tumor size. Both findings should modify the prevailing view that metastatic dissemination is a late event and that the association of tumor size and risk for metastasis reflects a higher frequency of tumor cell seeding. Implicit in this view is the supposition that extended periods of genetic progression within the primary tumor are required for metastatic dissemination, which our findings do not support. Chromosomal aberrations in DTCs—either of the BALB-neuT mouse model or of human breast cancers—are not associated with increased tumor size though they accumulate over time in human cancer as amply shown by Mitelman and Heim (Heim and Mitelman, 1995). Mouse models and human samples, therefore, concurred on...
the observation that relative to the total number of tumor cells in the primary lesion, dissemination is highest early after transformation.

Interestingly, in the BALB-NeuT model, activation of the proteolytic system in breast epithelia was associated with young age and ADH. Moreover, a quantitative analysis of Twist expression, comparing lesions with ADH, central and peripheral regions of a large tumor, and normal samples, revealed a significant upregulation in early-transformed breast cancer cells, exceeding even expression levels of the so-called invasion front of the primary tumor. Twist expression has been associated with epithelial-mesenchymal transition, migration, invasion, and cell-cycle deregulation (Stasinopoulos et al., 2005; Yang et al., 2004). The activation of a specific genetic program early after sex-hormone-induced expression of the transforming oncogene HER-2 may, thus, initiate microinvasion, which can be detected by transmission electron microscopy in breast lesions as early as in the stage of ADH. These lesions are defined as noninvasive, and no evidence of invasion was detected after careful light-microscopic inspection by an experienced pathologist (P.M.). Yet, both the BALB-NeuT and the PyMT mice harbored HER+ DTCs in lung and bone marrow and CK+ cells in bone marrow during ADH. Evidence for their malignant origin was provided by comparative genomic hybridization. An ectopic transgene expression at these sites could be excluded by the transplantation experiments where mammary grafts grew on wild-type background. Also here, epithelial cells disseminated to bone marrow and lungs at the stage of ADH and displayed genetic aberrations. The existence of a genetic program associated with dissemination but only transiently activated in early lesions might explain why in human breast cancer Twist expression was rarely found in invasive ductal carcinomas (Yang et al., 2004).

We performed several experiments to assess whether in mouse models, early-disseminated cancer cells may give rise to metastasis. First, growth of metastasis occurs during transition of primary lesions from noninvasive to invasive, which indicates that tumor cells had disseminated much earlier and started to grow at the distant site. Second, at week 18, when only in situ carcinomas were present, resection of the glands neither prevented nor reduced the number of lung metastases. Third, dissemination and early lung colonization were found also in wild-type females that had only transiently carried a single transgenic mammary graft. At resection, most grafts displayed only very small invasive cancers. In one of two cases where the transplant was surgically removed at the stage of ADH, the cells had started to form metastatic colonies when analyzed 10–13 weeks after surgery. Thus, while the number of experiments is currently too low to quantify the frequency of manifest metastasis as consequence of ADH, it is safe to state that early-disseminated tumor cells occasionally have metastatic potential. However, we noted that the course of the disease in the transplanted wild-type siblings was prolonged as compared to the transgenic animals with autochthonous tumors. While in BALB-neuT females metastases are regularly present at week 30, in wild-type mice (micro)metastases appeared only more than 40 weeks after transplantation of a transgenic gland. At least two possibilities may account for this observation: Although we transplanted the mammary tissue before expression of the transgene into recipient mice, which should result into peripheral immunological tolerance, we cannot exclude that immunosurveillance against the rat transgene product slowed down systemic cancer progression. Alternatively, surgical removal of the primary lesions at very early time points may deprive early-disseminated cancer cells from systemically acting factors important for outgrowth. Such factors secreted from the primary tumor may prepare the metastatic niche and foster early cancerous colonies as recently suggested (Kaplan et al., 2005). Thus, large primary breast cancers in patients may support metastasis not by seeding more cancer cells, but by providing unknown systemically acting factors that stimulate colonization of previously disseminated tumor cells at the ectopic site. This reasoning is backed by findings that patients with small (T1-stage) tumors harbor similar numbers of disseminated cancer cells as patients with late stage tumors (T3 to T4) present in our cohort of 607 patients. In a meta-analysis of several studies on DTCs in breast cancer, employing, however, rather different techniques for DTC detection but totalizing more than 4700 patients, Braun and coworkers observed an increase of positive bone marrow samples from 22% in stage T1 to 34% in stage T3 (Braun et al., 2005). These data give further support to the conclusions that large tumors in relation to small tumors seed far less tumor cells to bone marrow: On average, primary T3 tumors comprise about 350 times more cancer cells than T1-stage tumors, but the percentage of patients with DTCs in bone marrow increases only marginally. Thus, the poorer prognosis of patients with T3-stage breast cancers cannot be explained by increased DTC numbers, but so far unknown external triggers may be responsible for metastatic outgrowth that currently are rather underestimated. In this context, it is noteworthy that while the highest number of DTC in bone marrow during the lifetime of BALB-neuT mice never exceeds 10⁴ bone marrow cells, transplantation of transgenic bone marrow containing a total of about 80 tumor cells per inoculum taken from 11-week-old BALB-neuT mice and injected into irradiated wild-type animals resulted in bone marrow carcinosis with more than 30% of all cells being of cancerous origin. Since the donor bone marrow had been taken from mice with ADH, this suggests that the tumor cells may be released from dormancy or some type of quiescence—possibly as consequence of the stimulatory microenvironment during repopulation of the irradiated bone marrow compartment—and eventually grow out.

Though the finding of microinvasion at the stage of ADH may not apply to all patients with breast cancer, the detection itself of disseminated cancer cells in DCIS suggests that conventional histopathological analysis may miss tumor spread in human cancer as well. Although very rare, metastasis in DCIS patients has been observed despite complete resection of their mammary tissue (Cutuli et al., 2001). Other well-known clinical findings, such as cancer of unknown primary (van de Wouw et al., 2002) as well as inadvertent transfer of cancer with organ transplants from donors with small undiagnosed malignant lesions (Riethmuller and Klein, 2001), are equally consistent with early dissemination and potential metastatic outgrowth.

Taken together, our findings suggest a concept of cancer progression according to which metastatic dissemination is a distinct early step in cancer progression being necessary, but not sufficient, for metastatic outgrowth. The interactions of early-disseminated cancer cells with their ectopic microenvironment leading to selection or adaptation within an early metastatic
niches are ill understood at present and may require different experimental approaches than the frequent use of cell lines derived from late stage tumors. Previous work and the present work demonstrate that essential steps of genetic progression take place at the ectopic site and not within the primary tumor. The understanding of which mechanisms promote the outgrowth of DTCs often after extended periods of cancer latency might be key to the prevention of the lethal metastases.

**EXPERIMENTAL PROCEDURES**

**Mice**

BALB-NeuT and MMTV-PyMT mice transgenic mice were maintained in our facilities according the European Union guidelines. All animal experiments were performed according to the EU and national institutional regulations. Mice were screened at 3 to 4 weeks of age for hemizygosity (neuT+/neuT–), and negative littersmates served as wild-type BALB/c mice controls. Mammary glands of BALB-NeuT female mice were inspected twice a week and arising tumors were measured with calipers in two perpendicular diameters (Boggio et al., 1998). Tissue samples from transgenic MMTV-PyMT mice (FVB strain) were obtained from Christoph Peters and Thomas Reinecke (Institute for Molecular Medicine, University of Freiburg).

**Bone Marrow Preparation**

After sterile preparation of both femurs, bone marrow was rinsed with a 26-G needle in 1 ml of PBS. After density gradient centrifugation, 5 × 10^6 interphase cells were dropped on adhesion slides (Menzel, Germany). At least 10^5 cells per mouse were stained, and positive cells were isolated using a micromanipulator.

**Immunostaining**

For the detection of disseminated cells, anti-CK 8 and 18 (GP11, Progen, Germany) and anti-HER-2 (c-erbB2, Dianova, Germany) antibodies were used in a concentration of 5 μg/ml and visualized by ABC complex/AP (Dako, Denmark) using the AP substrate BCIP/NBT (Biorad, Germany). For HER-2 immunohistochemistry of solid tissues, 5 μm cryosections of primary tumors or lung tissue were stained. For MMP2 immunohistochemistry, formaldehyde-fixed tissues were embedded in paraffin wax. Rabbit polyclonal anti-MMP-2 (Chemicon International, AB809) was applied in a 1:250 dilution.

**Laser Microdissection, DNA, and mRNA Preparation**

Laser microdissection, single-cell isolation, and nucleic acid preparation for DNA and mRNA was performed as described previously (Klein et al., 2002a, 2002b; Schmidt-Kittler et al., 2003). Small pieces summing up to 100,000 μm² for each sample were catapulted into a cap with 6 μl PCR oil and centrifuged into a 200 μl reaction tube (for DNA) while for mRNA analysis the tissues were catapulted into reaction tubes containing 10 μl paramagnetic oligo-dT bead suspension and lysis buffer (Dynal).

**Quantitative PCR**

Real-time PCR was performed using a LightCycler (Roche) and Fast Start Master SYBR Green Kits (Roche). Analysis was done using the RelQuant software (Roche) with PCR efficiency normalization and a reference sample included in every run. Pooled mRNA from TUBO cells (Curcio et al., 2003) served as positive control. Measurements showing unspecific products in the melting curve analysis were discarded from further analysis. All expression levels are given relative to Gapdh (primer sequences are provided in Table S4).

**Comparative Genomic Hybridization, Image Acquisition, and Analysis**

Murine control DNA and tumor DNA were labeled with biotin-16-dUTP and digoxignin-12- dUTP (Roche Germany), respectively, and detected after hybridization to metaphase chromosomes using anti-DIG-FITC Fab Fragments (200 μg/ml, Roche, Germany) and biotinylated normal DNA by avidin-Cy 3.5 (Rockland, USA). Images were recorded by a Leica DMXA-RF8 microscope (Leica acquisition program QFISH) equipped with a Sensys CCD camera (Photometrics, USA). Processing and karyotyping was done using the Leica software package Q-CGH.

**Array Hybridization and Analysis**

After global mRNA amplification, PCR-amplified cDNA fragments were digoxigenin labeled and nonradioactively hybridized to nylon filters (Klein et al., 2002a). Scanning and significance analysis (SAM) was performed as published (Tusher et al., 2001; Zohlnhofer et al., 2001). The clustering of proteases was done for the Euclidean distances, complete linkage for proteases, and average linkage for cases. Cluster assessment was performed using BRB ArrayTools developed by Dr. Richard Simon and Amy Peng (McShane et al., 2002).

**Calculation of Tumor Progression over Time**

Tumor areas were calculated from 407 mammary glands of 41 mice assuming the shape of an ellipse/circle for each tumor. The tumor size/area of a mammary gland without a tumor was set to zero. The curve was fitted using Friedman’s scatterplot smoother, HER-2+ cells from 31 samples (28 mice) and CK+ cells from 33 samples (31 mice) were calculated as the sum of single disseminated cells and the number of aggregates. Measurements from similar time points (± 1 week) were consolidated. An offset of ±0.3 weeks was used to draw HER-2+ (~9.3) and CK+ (+0.3) cells in one plot. The number of CK+ and HER-2+ cells from nontransgenic BALB/c mice were measured in 25 mice (CK) and 24 mice (HER-2) at five time points (weeks 4, 9, 18, 22, and 29) and connected by a dotted line. The area of lung metastases was measured using the PALM Robo V1.2.3 software and calculated as sum of all metastases found. Values were averaged over two tissue sections. The size of metastases was measured from four mice with and 14 mice without surgery, and measurements from similar time points (± 2 week) were consolidated.

**Surgery of Mammary Tumors**

Mice were anaesthetized with ketamin 80–120 mg i.p. and xylazin 5 mg i.p sufficient for 90–120 min. Thorax and abdomen were shaved, skin was incised from caudal to cranial in the midline, and subcutaneous tissue was prepared, i.e., the breast glands together with fatty tissue, and resected in toto after coagulation of vessels. The skin was closed by a suture using prolene, 4-0. Ethicon, Germany. Surgery took usually 30–60 min and mice were kept under a warming lamp until awakening. Postoperative analgesia was achieved by 25 mg metamizol every 4 hr p.o. After 8 days, sutures were removed.

**Tissue Transplantation**

Surgical techniques and the transplantation procedure has been previously described (Daniel et al., 1968; Deome et al., 1959). Briefly, the nipple region from the fourth fat pad on the right side of 3-week-old recipient BALB/c mice was removed under anesthesia. Then, a piece of donor mammary tissue (approximately 1 to 2 mm in size) from 3- to 12-week-old BALB-neuT mice was implanted in the “cleared” mammary fat pad of recipient mice.

**Bone Marrow Transplantation**

Eleven-week-old BALB-NeuT mice were euthanized and bone marrow was harvested from femurs and tibiae. 7.9 × 10^6 bone marrow cells injected into the tail vein of 11 week-old lethally irradiated (split dose day –2 and day 0: 550 rad) wild-type siblings. From the remaining bone marrow, slides were prepared as described above to determine tumor load by CK staining.

**Analysis of Breast Cancer Patients**

From our previous study on disseminated breast cancer cells, we included all 270 nonmetastatic patients (T1-4, N0-2, M0) for which information on T-stage was available and four patients with DCIS. Cytokeratin-positive cells were detected and isolated for genetic analysis, and their DNA was amplified for comparative genomic hybridization as described before (Schmidt-Kittler et al., 2003). In addition, 298 breast cancer patients with unilateral primary breast cancer (T1–T4, N0–N2, M0) and 35 patients with DCIS undergoing surgery at the Department of Oncology and Obstetrics, University of Tübingen, Germany, were included. Bone marrow sampling, preparation, staining, and screening were performed according to the consensus protocol for the detection of disseminated cancer cells (Fehrm et al., 2006) applying the mab A45-B/B3 antibody (Miltenyi, Germany). All bone marrow samples were taken with the approval of local ethics committees and after obtaining informed consent.
of the patients. Data for the control group of normal individuals, including 191 patients with nonmalignant disease (153 patients with benign lesions of the breast, such as fibroadenomas, mastitis, abscesses, and cysts; 11 with simple cysts; 10 with cystadenoma of the ovaries; and 17 with cervical intraepithelial neoplasms of grade I or II), was taken from the study of Braun et al. (2000).

Supplemental Data
The Supplemental Data include four supplemental figures and four supplemental tables and can be found with this article online at http://www.cancercell.org/cgi/content/full/13/1/58/DG1/.

ACKNOWLEDGMENTS
We gratefully acknowledge the generous help of Bernd Wiederanders for providing us the mouse cDNA array, and Thomas Reinecke and Christoph Peters for help with the PyMT mice. We thank Andrea Boel for excellent animal care and Melanie Werner-Klein for help with bone marrow transplantation experiments. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Ki-1233); the Wilhelm-Sander Stiftung (1999.047.2); the German Federal Ministry for Education and Science (BioFuture Grants 0311884 and 0311880; NGRF 01GR0101); the Bavarian State Ministry of Sciences, Research and the Arts; the EU-FP6 (MCSC); the Italian Association for Cancer Research; the Italian Ministry for Education, University and Research; and a scholarship from the Jung-Stiftung, Hamburg (J.B.G.).

REFERENCES


Accession Numbers

cDNA microarray data have been deposited into ArrayExpress (www.ebi.ac.uk/arrayexpress/) under the number E-MEXP-1381.